Share this article and save a life!
Everyone is celebrating the SAFFRON trial. I want to slow down. 🧬
The headlines are right that this is significant. But the most important thing SAFFRON gives us is not a drug combination. It is a decision framework for what to do BEFORE you ever reach for a salvage regimen.
Here is how I think thoracic tumor boards should use this data.
—
THE SAFFRON RESISTANCE EVALUATION FRAMEWORK
For EGFR-mutated NSCLC progressing on osimertinib
1. CONFIRM THE RESISTANCE MECHANISM FIRST
SAFFRON required prospective eligibility based on high MET overexpression and/or amplification, determined by IHC for protein expression and FISH for gene amplification, according to Pharmacy Times. That is not optional context. That is the protocol. Molecular testing at progression is not a nice-to-have. It is the gate.
2. UNDERSTAND WHAT MET IS ACTUALLY DOING
MET activation enables bypass signaling after EGFR TKI therapy. The cancer is not just mutating. It is rerouting. Dual EGFR/MET inhibition is designed to suppress MET-driven resistance while maintaining EGFR pathway blockade. If you treat resistance without knowing the mechanism, you are guessing.
3. KNOW WHAT YOU ARE COMPARING AGAINST
SAFFRON compared the all-oral combination of osimertinib 80 mg once daily plus savolitinib 300 mg twice daily against platinum-pemetrexed with pemetrexed maintenance. That is the relevant benchmark. Platinum doublet chemotherapy is still the floor. The question is who qualifies for something better.
4. READ THE TRIAL SCOPE CAREFULLY
SAFFRON randomized 338 patients across 29 countries. Both the primary endpoint of progression-free survival and the key secondary endpoint of overall survival met statistical significance. It is the first global phase 3 trial to demonstrate dual PFS and OS benefit in this resistance subset. That matters for how you weight this data at tumor board.
5. HOLD ON THE GRADE 3 TOXICITY DETAILS
Safety was consistent with known osimertinib and savolitinib profiles. But detailed grade 3 or higher toxicities and dose-modification rates are still awaited. Do not build your patient conversations around a complete safety profile that has not been published yet.
—
Where this breaks down in practice:
Most community thoracic programs are not reflexively testing for MET overexpression and amplification at progression. They are moving to chemotherapy by habit, not by data.
SAFFRON does not just validate a drug combination. It validates a molecular sequencing discipline that most programs have not built yet.
The oncologists who will use this data well are the ones who already have a reflex testing protocol at EGFR resistance. The ones who do not will read the headline and wait for their institution to catch up.
If your tumor board does not have a written protocol for molecular workup at EGFR TKI progression, save this before your next MTB and use the five steps above as a starting checklist.
👉 Follow Jonathan Govette, CEO of Oatmeal Health, for daily healthcare insights on LinkedIn. Deeper dives in The Oatmeal Bite on Substack: https://news.oatmealhealth.com
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
